Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of AKB-9090 in Healthy Adults
NCT07429006Phase 1Recruiting
- Sponsor
- Akebia Therapeutics
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anemia comparing AKB-9090 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at Day 7, Clinically Significant Changes in Physical Examinations at Day 7 and 7 more. Started Mar 2026; status: recruiting.
02
Drugs
AKB-9090
03
Conditions
anemia
Beyond the preview
Go deeper on NCT07429006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429006.